>
Switch to:

Orgenesis Effective Interest Rate on Debt %

: 5.34% (As of Dec. 2021)
View and export this data going back to 2010. Start your Free Trial

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Orgenesis's annualized positive value of Interest Expense for the quarter that ended in Dec. 2021 was $0.66 Mil. Orgenesis's average total debt for the quarter that ended in Dec. 2021 was $12.35 Mil. Therefore, Orgenesis's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2021 was 5.34%.

Orgenesis Effective Interest Rate on Debt % Historical Data

The historical data trend for Orgenesis's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Annual Data
Trend Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21
Effective Interest Rate on Debt %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.07 48.23 5.70 9.40 7.62

Orgenesis Quarterly Data
Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Effective Interest Rate on Debt % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.56 7.86 8.48 7.94 5.34
Competitive Comparison

For the Biotechnology subindustry, Orgenesis's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   
Orgenesis Effective Interest Rate on Debt % Distribution

For the Biotechnology industry and Healthcare sector, Orgenesis's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Orgenesis's Effective Interest Rate on Debt % falls into.


Orgenesis Effective Interest Rate on Debt % Calculation

Orgenesis's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2021 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2020 )+Total Debt  (A: Dec. 2021 ))/ count )
=-1  *  -0.943/( (12.907+11.84)/ 2 )
=-1  *  -0.943/12.3735
=7.62 %

where

Total Debt  (A: Dec. 2020 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=8.284 + 4.623
=12.907

Total Debt  (A: Dec. 2021 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=5.456 + 6.384
=11.84

Orgenesis's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2021 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2021 )+Total Debt  (Q: Dec. 2021 ))/ count )
=-1  *  -0.66/( (12.865+11.84)/ 2 )
=-1  *  -0.66/12.3525
=5.34 %

where

Total Debt  (Q: Sep. 2021 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=7.989 + 4.876
=12.865

Total Debt  (Q: Dec. 2021 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=5.456 + 6.384
=11.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2021) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Orgenesis  (NAS:ORGS) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Orgenesis Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Orgenesis's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orgenesis Business Description

Orgenesis logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Comparable Companies
NAS:CASI ROCO:6461 NAS:PRTG XKRX:291650 NAS:ENTX TSE:4588 OSTO:ACE NAS:EYEN TSX:ONC XKRX:072520
Traded in Other Exchanges
45O:Germany 45O:Germany
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Website
https://www.orgenesis.com
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Executives
Sidransky David director JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205
Reithinger Neil officer: CFO, Treasurer and Secretary 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260
Philips Mario director C/O ATMI, INC DANBURY CT 06810
Ferber Sarah officer: Chief Scientific Officer 17B HAHASKALA STREET TEL AVIV L3 67890
Yachin Guy director 7 ORCHARD WAY N POTOMAC MD 20854
Nanda Ashish director 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452
Bedoret Denis officer: See Remarks 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041
Universite Libre De Bruxelles other: less than 10% AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050
Theodorus Ii Sa other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Theodorus Sca other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Belenger Olivier other: less than 10% DIEWEG, 69 BRUSSELS C9 1070
Shvartz Oded 10 percent owner 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000
Bultot Hugues director AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150
Buyse Chris Georges Frans director BAILLET LATOURLEI 119A BRUSSELS C9 2390
Tenne Joseph officer: CFO Treasurer Secretary 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511

Orgenesis Headlines

From GuruFocus

Orgenesis Stock Appears To Be Modestly Overvalued

By 06-23-2021

Orgenesis Achieves Multiple Ranpirnase Development Milestones

By Marketwired 07-06-2021

Orgenesis Schedules Second Quarter 2021 Business Update Conference Call

By Marketwired 08-03-2021

Orgenesis Schedules Third Quarter 2021 Business Update Conference Call

By Don Li2 11-02-2021

Orgenesis Announces Anti-Viral “BioShield” Program Designed to Potentially Increase Preparedness, Rapidly Address Virus Spread and Protect Against Future Outbreaks such as COVID-19

By Marketwired 06-10-2020

FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2 to Treat ARDS Resulting from COVID-19 Infection

By Marketwired 05-06-2021

Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea

By Marketwired 03-08-2021

Orgenesis Schedules Fiscal 2020 Year-End Business Update Conference Call

By Marketwired 03-04-2021

Orgenesis to Present at the Summer Solstice Conference - Best Ideas from the Buy-Side on June 2nd

By Marketwired 06-01-2021

Orgenesis Added to Russell 3000® Index

By Marketwired 06-29-2020

Other Sources

$ORGS - Orgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results - Earnings Call Transcript.…

By Seekingalpha 2021-11-06

$ORGS - Orgenesis: A Cell And Gene Therapy Disruptor With A Nice Risk Reward Profile. Orgenesis Cell And Gene Therapy Disruptor Nice Risk Reward Profile

By Seekingalpha 2021-01-28

$ORGS - Orgenesis: A Mispriced Visionary In Cell And Gene Therapy Manufacturing. Orgenesis A Mispriced Biotech Visionary

By Seekingalpha 2021-05-17

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)